Beryllium is a chemical element widely used in the mining industry and in the manufacturing of many products like planes, engines and satellites. In spite of its widespread use, Beryllium was identified as a carcinogen. The hazards of exposure to its compounds leads to the development of lung cancer and chronic beryllium disease (CBD), a disease that might be fatal in the absence of early diagnosis. In Canada, CBC is recognized as an occupational disease and therefore strict exposure monitoring and surveillance standards in the workplace is applied in many industries. The beryllium lymphoproliferation test (BeLPT) is the first clinical step in screening beryllium sensitivity using ex vivo T cell proliferation assay. It consists in determining if the individual’s while Peripheral Blood Mononuclear Cells (PBMCs) significantly proliferate in the presence of beryllium. Immuni T’s BeLPT testing platform follows strict international guidelines and is entitled an hematology permit from the Institut de Santé Publique du Québec.